Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Clinical Imbalances

Immune and inflammation

Modifiable Lifestyle Factors

Diet

Laboratory Testing

Tissue biopsy

Text Availability

Abstract

1449

Full text

1193

Free full text

682

Publication Types

Journal Article

1478

Research Support, Non-U.S. Gov't

617

Clinical Trial, Phase II

485

Randomized Controlled Trial

463

Multicenter Study

427

Review

252

Clinical Trial

228

Clinical Trial, Phase III

208

Comparative Study

175

Clinical Trial, Phase I

123

Research Support, N.I.H., Extramural

Case Reports

Meta-Analysis

Observational Study

Systematic Review

Letter

Comment

Research Support, U.S. Gov't, P.H.S.

Clinical Trial Protocol

Editorial

Controlled Clinical Trial

Equivalence Trial

Evaluation Study

Network Meta-Analysis

Validation Study

Research Support, N.I.H., Intramural

Research Support, U.S. Gov't, Non-P.H.S.

Clinical Trial, Phase IV

Consensus Development Conference

Practice Guideline

Video-Audio Media

Retracted Publication

Historical Article

News

Pragmatic Clinical Trial

Interview

Webcast

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

107

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Organoplatinum Compounds""[mesh_terms]

1510 Results

Searching titles within these results

Literature review and practical aspects on the management of oxaliplatin-associated toxicity.

Paulo M Hoff, Everardo D Saad, Frederico Costa, Anelisa K Coutinho, Ricardo Caponero, Gabriel Prolla, Rene C Gansl

Clinical colorectal cancer 2012;11(2):93-100

Full Text

Abstract

Chronotherapy for cancer.

M Eriguchi, F Levi, T Hisa, H Yanagie, Y Nonaka, Y Takeda

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2004;57 Suppl 1():92s-95s

Full Text

Abstract

Oxaliplatin-related side effects: characteristics and management.

Jean-Louis Misset, Jim Cassidy

Seminars in oncology 2002;29(5 Suppl 15):11-20

Full Text

Abstract

Clinical effects of bevacizumab targeted treatment on advanced colorectal cancer with liver metastasis.

W-H Lv, Y Zhao, X-D Li, M-Q Zhang

European review for medical and pharmacological sciences 2017;20(11):2249-55

Free Full Text

Abstract

Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity.

Guido Cavaletti, Jordi Bruna, Susanna B Park, Andreas A Argyriou

Journal of the peripheral nervous system : JPNS 2020;24(4):360-361

Full Text

Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.

F Wen, Y Zhou, W Wang, Q C Hu, Y T Liu, P F Zhang, Z D Du, J Dai, Q Li

Annals of oncology : official journal of the European Society for Medical Oncology 2013;24(1):171-8

Free Full Text

Abstract

Mechanistic studies on the reactions of platinum(II) complexes with nitrogen- and sulfur-donor biomolecules.

Živadin D Bugarčić, Jovana Bogojeski, Biljana Petrović, Stephanie Hochreuther, Rudi van Eldik

Dalton transactions (Cambridge, England : 2003) 2013;41(40):12329-45

Full Text

Abstract

Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.

Przemysław Czeleń, Beata Szefler

International journal of molecular sciences 2023;24(2):1548

Free Full Text

Abstract

A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.

Takashi Ura, Kei Muro, Hiroya Taniguchi, Yukiya Narita, Seiichiro Mitani, Keiji Sugiyama, Toshiki Masuishi, Shigenori Kadowaki

International journal of clinical oncology 2021;26(4):701-707

Full Text

Abstract

TRIBE2 results and toxicity.

Francesco Giuliani, Antonio Avallone

The Lancet. Oncology 2020;21(6):e299

Full Text

Evolution of systemic therapy for metastatic colorectal cancer.

J Ian Geh, Yuk Ting Ma

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2012;13(8):852-4

Full Text

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).

Nicolas Moosmann, Stefan Kasper, Meinolf Karthaus, Dominik Paul Modest, Verena Keitel, Christian Junghanß, Volker Heinemann, Sebastian Stintzing, Andreas Jung, Klaus Kaczirek, Sylvie Lorenzen, Swantje Held, Dagmar Sent, Christian Lerchenmüller, Florian Kaiser, Martin Fuchs, Ludwig Fischer V Weikersthal, Lutz Jacobasch, Jens Uhlig, Alexander Kiani

European journal of cancer (Oxford, England : 1990) 2022;173():297-306

Full Text

Abstract

Molecular aspects of resistance to antitumor platinum drugs.

Jana Kasparkova, Viktor Brabec

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;5(3-4):147-61

Full Text

Abstract

FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?

Richard Kim

The Lancet. Oncology 2011;12(1):8-9

Full Text

A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.

F Montagnani, A Chiriatti, G Turrisi, G Francini, G Fiorentini

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2012;13(8):846-52

Full Text

Abstract

Results: 1 – 15 / 1510

Filters

Expert Opinion

Clinical Imbalances

Modifiable Lifestyle Factors

Laboratory Testing

Text Availability

Publication Types

Publication Year

Results for ""Organoplatinum Compounds""[mesh_terms]

Literature review and practical aspects on the management of oxaliplatin-associated toxicity.

Chronotherapy for cancer.

Oxaliplatin-related side effects: characteristics and management.

Clinical effects of bevacizumab targeted treatment on advanced colorectal cancer with liver metastasis.

Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity.

Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.

Mechanistic studies on the reactions of platinum(II) complexes with nitrogen- and sulfur-donor biomolecules.

Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.

A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.

TRIBE2 results and toxicity.

Evolution of systemic therapy for metastatic colorectal cancer.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).

Molecular aspects of resistance to antitumor platinum drugs.

FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?

A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.

Results for
""Organoplatinum Compounds""[mesh_terms]